An evaluation of the neuroprotective effects of melatonin in an in vitro experimental model of age-induced neuronal apoptosis
Version of Record online: 31 JAN 2009
© 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard
Journal of Pineal Research
Volume 46, Issue 3, pages 262–267, April 2009
How to Cite
Tajes Orduña, M., Pelegrí Gabalda, C., Vilaplana Hortensi, J., Pallàs LLiberia, M. and Camins Espuny, A. (2009), An evaluation of the neuroprotective effects of melatonin in an in vitro experimental model of age-induced neuronal apoptosis. Journal of Pineal Research, 46: 262–267. doi: 10.1111/j.1600-079X.2008.00656.x
- Issue online: 13 MAR 2009
- Version of Record online: 31 JAN 2009
- Received October 17, 2008; accepted November 25, 2008.
- cell cycle;
Abstract: The neuroprotective effects of melatonin in an experimental model of aging-induced apoptosis have been examined. Cerebellar granule neurons show characteristics of apoptosis after 17 days in culture (DV). The addition of melatonin to neuronal cell cultures (100–500 μm) resulted in neuroprotective and antiapoptotic effects, which were revealed by nuclear condensed cell counting. In a thorough analysis by Western-blot of the potential pathways responsible for melatonin’s neuroprotective effects, we found an increase in the activation of prosurvival Akt. Subsequently GSK3β inhibition and an increase in p-FOXO1 phosphorylation occurred. In this model of aging, apoptosis was associated with an elevated DNA damage, as demonstrated by an increase in the activation of ataxia telangiectasia muted (ATM). Subsequently, downstream targets such as p53 were activated. Furthermore, the process of DNA damage was coupled to an increase in the expression of certain proteins involved in cell cycle regulation; these were cyclin D and the proapoptotic transcription factor E2F-1. We conclude that the antiapoptotic effects of melatonin were mediated by two potential mechanisms: by increasing the activity of prosurvival pathways via Akt and by the prevention of DNA damage (via ATM inhibition) followed by the reduction of cell cycle re-entry.